Clinical Trials Browser

Phase 3 × Recruiting × Ramucirumab × Clear all

NCT06123494 2024-01-16

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Phase 3 Recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma